| A network of conserved synthetic lethal interactions for exploration of precision cancer therapy R Srivas, JP Shen, CC Yang, SM Sun, J Li, AM Gross, J Jensen, K Licon, ... Molecular cell 63 (3), 514-525, 2016 | 162 | 2016 |
| Diet and feeding pattern modulate diurnal dynamics of the ileal microbiome and transcriptome ACD Machado, SD Brown, A Lingaraju, V Sivaganesh, C Martino, A Chaix, ... Cell reports 40 (1), 2022 | 54 | 2022 |
| Protein tyrosine phosphatases: mechanisms in cancer V Sivaganesh, V Sivaganesh, C Scanlon, A Iskander, S Maher, T Lê, ... International journal of molecular sciences 22 (23), 12865, 2021 | 33 | 2021 |
| Emerging immunotherapies against novel molecular targets in breast cancer V Sivaganesh, N Promi, S Maher, B Peethambaran International Journal of Molecular Sciences 22 (5), 2433, 2021 | 24 | 2021 |
| Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition JP Shen, R Srivas, A Gross, J Li, EJ Jaehnig, SM Sun, ... Oncotarget 6 (34), 35755, 2015 | 16 | 2015 |
| Structure–activity relationship of 2-aminodibenzothiophene pharmacophore and the discovery of aminobenzothiophenes as potent inhibitors of Mycobacterium smegmatis SH Alelaiwi, JE Heindl, V Sivaganesh, B Peethambaran, JR McKee Bioorganic & Medicinal Chemistry Letters 63, 128650, 2022 | 4 | 2022 |
| The Role of ROR1 in Targeted Prostate Cancer Treatment and Malignant Progression V Sivaganesh Saint Joseph's University, 2023 | 2 | 2023 |
| Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer V Sivaganesh, B Peethambaran Exploration of Targeted Anti-tumor Therapy 4 (6), 1188, 2023 | 1 | 2023 |
| RAD17 loss of function is synthetically lethal with the checkpoint kinase inhibitors AZD7762 or MK-1775 JP Shen, R Srivas, A Bojorquez-Gomez, K Licon, V Sivaganesh, JL Xu, ... Cancer Research 75 (15_Supplement), 129-129, 2015 | 1 | 2015 |
| Pentagalloyl Glucose (PGG) Exhibits Anti-Cancer Activity against Aggressive Prostate Cancer by Modulating the ROR1 Mediated AKT-GSK3β Pathway V Sivaganesh, TM Ta, B Peethambaran International Journal of Molecular Sciences 25 (13), 7003, 2024 | | 2024 |
| Penta-O-galloyl-ꞵ-D-glucose (PGG) targets aggressive androgen independent prostate cancer by ROR1 inhibition V Sivaganesh, A Iskander, T Ta, B Peethambaran Molecular Biology of the Cell 34 (2), 2023 | | 2023 |
| Receptor Tyrosine Kinase‐like Orphan Receptor 1 (ROR1) as a Selective Molecular Target in Androgen‐Dependent and Androgen‐Independent Prostate Cancer V Sivaganesh, N Promi, S Maher, B Peethambaran The FASEB Journal 35, 2021 | | 2021 |
| Inhibiting ROR1 expression in Androgen-Independent Prostate Cancer Reduces Aggressive Cancer Phenotypes by modulation of AKT-GSK3ꞵ Pathway V Sivaganesh, N Promi, S Maher, B Peethambaran | | 2021 |
| 350–Gwas-Identified Metabolic Syndrome Genes are Tightly Linked to Race N Easwar, SD Brown, A Desalermos, V Sivaganesh, AS Parnell, A Rajput, ... Gastroenterology 156 (6), S-71, 2019 | | 2019 |
